$19.73
+0.26 (+1.34%)
Open$20.41
Previous Close$19.47
Day High$20.41
Day Low$19.27
52W High$31.00
52W Low$4.50
Volume—
Avg Volume21.1K
Market Cap26.48M
P/E Ratio—
EPS$-10.46
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-32.7% upside
Current
$19.73
$19.73
Target
$13.27
$13.27
$11.80
$13.27 avg
$20.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.74M | 18.13M | 17.61M |
| Net Income | 675.0K | 507.1K | 519.2K |
| Profit Margin | 3.4% | 2.8% | 3.0% |
| EBITDA | 1.03M | 911.5K | 901.4K |
| Free Cash Flow | 725.0K | 739.6K | 699.1K |
| Rev Growth | -5.2% | +2.0% | -8.0% |
| Debt/Equity | 1.19 | 0.81 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |